FRX: FOREST LABS A - Company News - Zacks Investment Research

ESTIMATES
Detailed Estimates

37.98

                        Forest Labs A: (NYSE: FRX)
                    

                                    $37.92
                                

                                    -0.06 (-0.16%)
                                

                                    Volume 665,333
                                

                                    May 21 04:01 PM ET
                                
Zacks Rank: 3-Hold  

                                
                                     
 
#3
 
 

                                
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                            
                                                                    Zacks Rank
                                                                    Definition
                                                                    Annualized Return
                                                                

                                                            
                                                                    #1
                                                                    Strong Buy
                                                                    26.6%
                                                                

                                                                    #2
                                                                    Buy
                                                                    18.71%
                                                                

                                                                    #3
                                                                    Hold
                                                                    10.12%
                                                                

                                                                    #4
                                                                    Sell
                                                                    4.32%
                                                                

                                                                    #5
                                                                    Strong Sell
                                                                    2.16%
                                                                

                                                                    S&P
                                                                    500
                                                                    9.93%
                                                                

                                                        Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
Company News


                    
                            Get Company News for:
                            


                

        News For FRX
    
May 21, 2013 Is There a Pill For That? Forest Labs??? Iffy Pipeline - YCharts
May 20, 2013 Pharma M&A ??? Actavis to Acquire Warner Chilcott - Benzinga
May 17, 2013 Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Conference - Businesswire
May 17, 2013 Potential Forest Laboratories (FRX) Trade Has $36.60 Breakeven - Freshbrewedmedia
May 16, 2013 Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting - Businesswire
May 16, 2013 Forest Labs Will Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting - Benzinga
May 14, 2013 Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week(R) 2013 - Businesswire
May 14, 2013 Shares of Forest Laboratories Rise Above Previous 52-Week High - Financial News Netwfork Online - 52-Week High-Lows
May 13, 2013 Forest Laboratories (FRX) Could Break Through $38.77 Resistance Level - Freshbrewedmedia
May 10, 2013 Analyst Moves:  MU, FRX, AES, CVC - Marketnewsvideo.Com
May 10, 2013 Analysts` Actions: MU BSX CVC FRX - TheStreet.com
May 10, 2013 Bacterial Partnering Terms and Agreements - 2013 Report Features Over 1,000 Links to Online Copies of Actual Bacterial Deals - M2
See all news
May 10, 2013 Forest and Almirall announce positive results from second Phase III COPD trial - Datamonitor
May 9, 2013 Dermatology Partnering Terms and Agreements - 2013 Report - M2
May 9, 2013 Treven And Forest Labs Reach Deal To Develop TRV027 To Treat Acute Heart Failure - M2
May 9, 2013 Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Heart Failure - Businesswire
May 9, 2013 Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure - Pr Newswire
May 9, 2013 Viral Partnering Terms and Agreements - 2013 Report Features Players such as AstraZeneca and Novartis - M2
May 8, 2013 Dermatology Partnering Terms and Agreements - 2013 - M2
May 8, 2013 Forest Laboratories Crosses Above its 10-day MA (FRX) - Financial News Network Online - Moving Average Crossovers
May 8, 2013 Gastrointestinal Partnering Terms and Agreements 2013: Latest Analysis from the World's Leadng Healthcare Companies - M2
May 8, 2013 Sensory Organ Partnering Terms and Agreements - M2
May 8, 2013 Stock Investors Bid Up Shares of Forest Laboratories, Up 1.9% - Financial News Network Online - Market Movers
May 7, 2013 Forest Laboratories (FRX) Showing Bullish Technicals With Resistance At $37.72 - Freshbrewedmedia
May 7, 2013 Forest Laboratories and Almirall Report Positive Results on Second Phase III Study for Aclidinium and Formoterol Combination in COPD - Close-Up Media
May 7, 2013 Next Support Level for Forest Laboratories (FRX) is $36.90 - Financial News Network Online - Pivot Alerts
May 6, 2013 Forest Laboratories and Almirall Confirm Positive Results from Augment COPD Clinical TrialSUBJECTCODE04011000 - Close-Up Media
May 6, 2013 Forest Laboratories and Almirall Report Study Results for Aclidinium and Formoterol Combination in COPD - Close-Up Media
May 5, 2013 Take a Deep Breath Before This Big FDA Decision - TheMotleyFool
May 3, 2013 Forest Laboratories (FRX) Breaks Through Resistance at $37.32 - Financial News Network Online - Pivot Alerts
May 2, 2013 Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Combination in COPD - Cnw Group
May 2, 2013 Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Combination in COPD - Pr Newswire Europe
May 2, 2013 Forest Laboratories reports lower Q4 net income, provides annual outlook - Datamonitor
May 1, 2013 Buyers Accumulating Shares of Forest Laboratories on 1.2x Above-Average Volume (FRX) - Financial News Network Online - Unusual Volume
May 1, 2013 Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD  - Benzinga
May 1, 2013 Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD - Businesswire
Apr 30, 2013 Forest Laboratories (FRX) Trading Near $36.87 Support Level - Freshbrewedmedia
Apr 30, 2013 Forest Laboratories has the Highest Future Earnings Growth in the Pharmaceuticals Industry (FRX, PTIE, CBRX) - Financial News Network Online - News Corner
Apr 29, 2013 Forest Laboratories (FRX) Crosses Pivot Point Resistance at $37.16 - Financial News Network Online - Pivot Alerts
Apr 27, 2013 3 Horrendous Health-Care Stocks This Week - TheMotleyFool
Apr 26, 2013 Endo Pharmaceuticals is Among the Companies in the Pharmaceuticals Industry With the Highest Free Cash Flow Per Share (ENDP, FRX, AGN) - Financial News Network Online - News Corner
Apr 26, 2013 Research and Markets Adds Report: Forest Laboratories - SWOT Framework Analysis - Close-Up Media
Apr 24, 2013 Forest Laboratories (FRX) Showing Bullish Technicals But Could Fall Through $35.22 Support - Freshbrewedmedia
Apr 24, 2013 Forest Laboratories Beats on Both Top and Bottom Lines - TheMotleyFool
Apr 24, 2013 Forest Laboratories Inc.Corporate Event Announcement Notice - Wall Street Horizon
Apr 23, 2013 Bill Nygren Comments on Forest Laboratories - GuruFocus
Apr 23, 2013 Buyers Accumulating Shares of Forest Laboratories on 1.4x Above-Average Volume (FRX) - Financial News Network Online - Unusual Volume
Apr 23, 2013 Earnings Scheduled For April 23, 2013 - Benzinga
Apr 23, 2013 Forest Laboratories Crosses Above its 10-day MA (FRX) - Financial News Network Online - Moving Average Crossovers
Apr 23, 2013 Forest Laboratories Inc.Corporate Event Announcement Notice - Wall Street Horizon
Apr 23, 2013 Forest Laboratories Shares Climbing Higher, Up 2.7% - Financial News Network Online - Market Movers
Apr 23, 2013 Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization - Businesswire
Apr 23, 2013 Forest Labs Guides In-line - Earningswhispers Earnings Guidance
Apr 23, 2013 Ironwood`s Constipation Drug Sales Disappoint - TheStreet.com
Apr 23, 2013 US Stock Futures Mixed; Apple Earnings In Focus - Benzinga
Apr 22, 2013 Forest Laboratories - 2013 SWOT Framework Analysis - M2
Apr 22, 2013 Research and Markets: Forest Laboratories - 2013 SWOT Framework Analysis - Businesswire
Apr 19, 2013 Forest Laboratories (FRX) Breaks Through Resistance at $35.67 - Financial News Network Online - Pivot Alerts
Apr 18, 2013 Forest Laboratories (FRX) Showing Bearish Technicals With Support At $34.98 - Freshbrewedmedia
Apr 18, 2013 Forest Laboratories Inc.Corporate Event Announcement Notice - Wall Street Horizon
Apr 17, 2013 Forest Laboratories Inc.Corporate Event Announcement Notice - Wall Street Horizon
Apr 17, 2013 Forest Laboratories has Relatively Underperformed its Peers in the  Pharmaceuticals Industry (FRX, JAZZ, AGN, RHHBY, TEVA) - Financial News Network Online - News Corner
Apr 16, 2013 A Peek Into The Market Before The Trading Starts - Benzinga
Apr 16, 2013 Almirall and Forest Laboratories Announce Positive Phase III Study Results for Aclidinium and Formoterol Combination in COPD - Businesswire
Apr 16, 2013 Almirall and Forest Laboratories Announce Positive Results of a Phase III Study for Aclidinium and Formoterol Combination in COPD - Cnw Group
Apr 16, 2013 Almirall and Forest Laboratories Announce Positive Results of a Phase III Study for Aclidinium and Formoterol Combination in COPD - Pr Newswire Europe
Apr 16, 2013 Almirall, Forest Labs Announce Positive Topline Phase III Study Results for Aclidinium, Formoterol Combination in COPD  - Benzinga
Apr 16, 2013 Cadence Pharmaceuticals had the Lowest Relative Performance in the Pharmaceuticals Industry (CADX, NKTR, FRX, JAZZ, VVUS) - Financial News Network Online - News Corner
Apr 16, 2013 Forest Laboratories (FRX) Breaks Through Support at $35.50 - Financial News Network Online - Pivot Alerts
Apr 16, 2013 Forest Laboratories Set to Possibly Rebound After Yesterday's Selloff of 1.19% - Comtex Smartrend(R)
Apr 16, 2013 Watch for Forest Laboratories to Potentially Rebound After Falling 1.19% Yesterday - Comtex Smartrend(R)
Apr 15, 2013 TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development - Pr Newswire
Apr 12, 2013 Forest Laboratories (FRX) Showing Bullish Technicals With Resistance At $38.71 - Freshbrewedmedia
Apr 10, 2013 Bigbiotech Partnering Yearbook 2013: Understand partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 10, 2013 Companion Diagnostics Partnering Yearbook 2013: Understand partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 10, 2013 Forest Laboratories Crosses Above its 10-day MA (FRX) - Financial News Network Online - Moving Average Crossovers
Apr 10, 2013 Generic Pharma Partnering Yearbook 2013: Understand partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 10, 2013 Infectives Partnering Yearbook 2013: Understand partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 10, 2013 Metabolic Partnering Yearbook 2013: Understand partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 10, 2013 Next Resistance Level for Forest Laboratories (FRX) is $37.76 - Financial News Network Online - Pivot Alerts
Apr 10, 2013 Specialty Pharma Partnering Yearbook 2013: Understand partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 9, 2013 Bigpharma Partnering Yearbook 2013: Understand M&A deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 9, 2013 Central Nervous System Partnering Yearbook 2013: Understand M&A deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 9, 2013 Hematology Partnering Yearbook 2013: Understand M&A deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 9, 2013 Merger and Acquisition Partnering Yearbook 2013: Understand M&A deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 9, 2013 Public Health Partnering Yearbook 2013: Understand M&A deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 8, 2013 Forest Laboratories (FRX) Trading Near $37.85 Resistance Level - Freshbrewedmedia
Apr 8, 2013 Forest Laboratories Sets Conference Call for Fiscal 2013 Fourth Quarter Earnings - Close-Up Media
Apr 8, 2013 Gastrointestinal Partnering Yearbook 2013: Understand the partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 8, 2013 Hospital Care Partnering Yearbook 2013: Understand the partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 8, 2013 Mylan, Akorn, Astex Pharma, and Forest Laboratories Under StockCall's Microscope - Pr Newswire
Apr 8, 2013 Oncology Partnering Yearbook 2013: Understand the partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 8, 2013 Preclinical Partnering Yearbook 2013: Understand partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 8, 2013 Psychiatry Partnering Yearbook 2013: Understand the partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 8, 2013 Respiratory Partnering Yearbook 2013: Understand the partnering deals and agreements entered into by the worlds leading healthcare companies - M2
Apr 8, 2013 The Global Cardiovascular Drugs Market to Decline at A CAGR Of 10.47 Percent over the Period 2012-2016 - M2
Apr 6, 2013 Bill Nygren Commentary on Oakmark Fund, First Quarter 2013 - GuruFocus
Apr 5, 2013 Pharma & Biotech Stock Outlook - Apr 2013 - Zacks.Com
Apr 5, 2013 Pharma & Biotech Stock Outlook - Apr 2013 - Zacks.Com
Apr 4, 2013 Forest Laboratories Schedules Conference Call for Fiscal 2013 Fourth Quarter Earnings - Close-Up Media

            Zacks Commentary For FRX
        
May 14, 2013 Zacks Blog: Forest-Trevena Ink Deal
May 07, 2013 Zacks Blog: Positive Data on Forest Combo Drug
May 03, 2013 Zacks Blog: Mylan Reports in line Earnings
Apr 24, 2013 Zacks Blog: Loss Widens at Ironwood
Apr 23, 2013 Zacks Blog: Forest Labs' Earnings Decline
Apr 22, 2013 Zacks Blog: Forest Labs Likely to Miss 4Q Earnings
Apr 18, 2013 Zacks Blog: Positive Data on Forest Candidate
Jan 22, 2013 Zacks Blog: Canada Approves Forest's Bystolic
Jan 16, 2013 Zacks Blog: Loss Widens at IRWD on Higher Costs
Jan 16, 2013 Zacks Blog: Company News for January 16, 2013
Jan 15, 2013 Zacks Blog: Market to Remain Tentative
Jan 15, 2013 Zacks Blog: Ahead of Wall Street - January 15, 2012

<a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="728" height="90" border="0" alt="" /></a>                

                            Quick Links
                        
Services

                                            Premium Services
Zacks Rank
Personal Finance
Commentary
Education

                                        
My Account

                                            Manage Account
Update Profile
Subscriptions
Preferences
Login/Password Help
Upgrade to Premium

                                        
Resources

                                            Help
FAQs
Disclosure
Privacy Policy
Performance
Site Map

                                        
Client Support

                                            Contact Us
Share Feedback
About Zacks
Careers
Advertise
Media

                                        
Follow Us
Facebook
Twitter
Linkedin
RSS
You Tube
Zacks Research is Reported On:

                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                        
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.